Fiche publication
Date publication
janvier 2020
Journal
Journal of investigational allergology & clinical immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr NGUYEN-THI Phi Linh
,
Pr BONNIAUD Philippe
Tous les auteurs :
Tiotiu A, Oster JP, Roux PR, Nguyen Thi PL, Peiffer G, Bonniaud P, Dalphin JC, de Blay F
Lien Pubmed
Résumé
Omalizumab is a human anti-IgE antibody approved for the treatment of severe allergic asthma (SAA). However, its effectiveness in SAA associated with chronic rhinosinusitis with nasal polyposis (CRSNP+) is less well documented. Objective: The aim of this study was to evaluate the real-life effectiveness of omalizumab in patients with SAA and CRSNP+ who tolerated and did not tolerate aspirin.
Mots clés
CRSNP+, Effectiveness of omalizumab, Severe allergic asthma
Référence
J Investig Allergol Clin Immunol. 2020 ;30(1):49-57
